Beyond a Large Panel: What Else Deserves the Budget
Ranked by expected value rather than by novelty, the highest-return health purchases are mostly unfashionable and several cost nothing.
The Short Answer
People considering a large testing package are usually deciding how to spend a health budget, and the package is one of many options competing for it. Ranked by expected value against cost, the list looks nothing like the market's emphasis. Several of the highest-return items are free, most of the paid ones are inexpensive and unglamorous, and the comprehensive panel sits in the middle rather than at the top.
The Free Tier, Which Outranks Everything Paid
Sleep regularity. A consistent wake time including weekends. Sleep regularity predicts mortality and cardiometabolic outcomes in large cohorts, in some analyses more strongly than duration.
Resistance training. Two or three sessions weekly, progressively loaded. Effects on muscle, bone, insulin sensitivity and function at every age, including the ninth decade.
Aerobic volume. Cardiorespiratory fitness is among the strongest predictors of all-cause mortality in prospective data.
Not smoking, and moderate alcohol.
Adequate protein and fibre, which is a shopping decision rather than a purchase.
Family history, properly established. Asking relatives about conditions and age at onset changes risk assessment more than most tests, and costs a conversation.
Power, impact and balance work. Roughly ten minutes a week, and it addresses the falls and fractures that end independence.
Social connection. Associated with mortality at effect sizes comparable to well-known physical risk factors.
Nothing purchasable outranks this tier, and buying anything before it is in place is optimising the margin.
The Cheap Tier: Under the Cost of One Panel
| Item | What it buys |
|---|---|
| Validated upper-arm blood pressure monitor | The silent risk factor with the strongest causal evidence, measured properly |
| Tape measure | Waist circumference, which tracks the metabolically active compartment |
| Hand dynamometer | Grip strength, which associates with mortality, disability and cognitive decline |
| A chair and a stopwatch | 30-second sit-to-stand and gait speed, both outcome-associated |
| Kitchen scales | Makes protein and energy intake knowable rather than guessed |
| A spreadsheet | The record, which is the asset that compounds |
| Resistance bands or a gym membership | The intervention with the broadest evidence |
The dynamometer deserves particular mention. It costs less than a month of most supplements and predicts more than most tests in this Journal, and almost nobody owns one.
Blood pressure is the standout for a different reason: it is silent, it has among the strongest causal evidence of any risk factor, clinic readings are frequently inaccurate, and home measurement across a week is the better estimate. A cuff is the single highest-value purchase in consumer health.
The Worthwhile Paid Tier
A deliberate blood panel, roughly twenty analytes chosen to answer questions, including apolipoprotein B, lipoprotein(a) once and fasting insulin. This is genuinely worth paying for and it is not a large panel.
Age-appropriate cancer screening through established programmes. Unglamorous, evidence-based, and among the highest-value health actions available. Frequently skipped by people spending substantially on optimisation.
A dental check, and care where needed. Periodontal inflammation contributes to systemic inflammatory markers and has been studied in relation to cardiovascular outcomes for decades.
An audiogram from midlife. Untreated hearing loss is among the largest identified modifiable dementia risk factors, and it is not on anyone's dashboard.
A DEXA at the guideline age, or earlier with risk factors, plus after any fragility fracture at any age.
A dermatological examination where skin cancer risk factors are present.
Vision correction and an eye examination, which also detects other conditions.
A clinician appointment to review existing results, often cheaper than a new panel and more useful.
Several of these are covered by routine care in many systems, which makes them free rather than merely cheap.
The Middling Tier
Reasonable purchases whose value depends on circumstances.
A monitoring device, if sleep regularity and activity volume are genuinely unknown to you. Read timing, activity, resting heart rate and their trends; ignore staging and proprietary scores.
A small supplement set: creatine, omega-3 where oily fish intake is low, and corrections for whatever the panel showed. Inexpensive and evidence-supported.
A cardiorespiratory fitness assessment, properly measured once, for a calibrated baseline and a training prescription.
Lactate threshold testing, if training seriously.
A coronary calcium score, where risk is intermediate, you are over 40, and a medication decision genuinely hangs on the result. A clinical conversation rather than a self-purchase.
Coaching, if the gap is adherence, which is frequently the case and rarely identified.
Better food, which is a genuine health purchase and rarely counted as one.
The Low-Value Tier
Not worthless in every case, and poor value against the alternatives above.
Comprehensive hundred-plus analyte panels, which generate meaningless findings by construction and cost several times a deliberate panel.
Biological age tests, interesting and not decision-changing, with test-retest variability exceeding achievable change.
Microbiome tests, where interpretation is unvalidated and the resulting advice is the same dietary advice available free.
Food sensitivity IgG panels, advised against by allergy societies, and the eliminations they generate reduce dietary variety.
Broad genetic and nutrigenomic panels, which rarely change management.
Multi-cytokine and organic acid panels.
Large multi-ingredient supplement stacks, particularly proprietary blends with undisclosed doses.
Intravenous vitamin infusions, which have no controlled evidence for the uses marketed and carry line risks.
Most at-home aesthetic and wellness devices, operating well below clinical energies.
Anything sold on a mechanism without human data at an achievable dose.
How to Decide for Yourself
Rather than accepting this ranking, three questions reproduce it.
Would the result change what I do? Name the two possible outcomes and the two responses. If they match, the purchase is information rather than a decision.
What is the evidence category? Outcome data, functional data, marker data, or mechanism. The free tier is supported by outcome data; much of the low-value tier by mechanism.
What is the next-best use of the same money? A comprehensive panel costs several deliberate panels, or a dynamometer plus a cuff plus a year of gym access, or a great deal of better food.
Applied honestly, those three questions push spending toward the boring end, which is where the evidence is. The market's emphasis runs the other way because the boring end is not sellable: nobody markets a tape measure as a longevity intervention, and nobody profits from a consistent wake time.
That asymmetry, rather than any disagreement about the science, explains most of the gap between what people buy and what works.
The AEONNN Perspective
This ranking is what AEONNN's Population and Evidence layers produce when applied to a spending decision, and it is uncomfortable for a paid platform to publish. The free tier outranks everything purchasable, and buying anything before sleep regularity, resistance training, aerobic volume and blood pressure control are in place is optimising the margin.
Two items in the cheap tier deserve more attention than they get. A validated upper-arm blood pressure monitor addresses the silent risk factor with the strongest causal evidence, and clinic readings are frequently inaccurate. A hand dynamometer costs less than a month of most supplements and predicts more than most tests in this Journal, and almost nobody owns one.
The worthwhile paid tier is mostly things routine care already offers and people spending heavily on optimisation frequently skip: age-appropriate cancer screening, a dental check, an audiogram from midlife, a DEXA at the guideline age. The market's emphasis runs the other way for a structural reason rather than a scientific one, which is that nobody markets a tape measure as a longevity intervention and nobody profits from a consistent wake time.
Pillar Matrix mapping
Database Matrix layers
- Meta / Consensus Layer (JAMA, BMJ, specialty society positions)
- Population Layer (UK Biobank, NHANES)
- Evidence Layer (PubMed, Cochrane, ClinicalTrials.gov)
- Quality / Formulation Layer (ConsumerLab, Labdoor)
Frequently Asked
What is the highest-value health purchase?
A validated upper-arm blood pressure monitor. Blood pressure is silent, has among the strongest causal evidence of any risk factor, and clinic readings are frequently inaccurate.
What outranks everything purchasable?
Sleep regularity, resistance training, aerobic volume, not smoking, adequate protein and fibre, family history established by asking, power and balance work, and social connection.
Is a comprehensive panel worth it?
A deliberate twenty-analyte panel including apoB, lipoprotein(a) once and fasting insulin is worth paying for. A hundred-plus analyte package generates meaningless findings by construction at several times the cost.
What do optimisers most often skip?
Age-appropriate cancer screening, a dental check, an audiogram from midlife and a DEXA at the guideline age. All are evidence-based and several are covered by routine care.
Why is a grip dynamometer worth buying?
Grip strength associates with all-cause mortality, cardiovascular events, disability and cognitive decline, and a dynamometer costs less than a month of most supplements.
What is poor value?
Hundred-plus analyte panels, biological age tests, microbiome tests, IgG food panels, broad nutrigenomic panels, multi-cytokine and organic acid panels, large proprietary stacks and intravenous vitamin infusions.
How do I judge a purchase myself?
Ask whether the result would change what you do, what evidence category supports it, and what the next-best use of the same money would be.
Evidence and review
Any dosage ranges cited here reflect the ranges used in published human trials, not personal recommendations. Evidence in this field moves, so this article is reviewed quarterly and carries its last-updated date above. Nothing here is intended as medical advice, and supplementation should be discussed with a qualified clinician, particularly alongside prescribed medication or an existing condition.